Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1998 2
2000 1
2001 1
2002 1
2003 1
2004 1
2005 1
2007 1
2009 3
2010 3
2011 2
2013 1
2015 1
2016 3
2017 3
2018 2
2019 2
2020 1
2021 5
2022 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

34 results
Results by year
Filters applied: . Clear all
Page 1
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY, Leonhard SE, Verboon C, Huizinga R, Drenthen J, Arends S, Budde IK, Kleyweg RP, Kuitwaard K, van der Meulen MFG, Samijn JPA, Vermeij FH, Kuks JBM, van Dijk GW, Wirtz PW, Eftimov F, van der Kooi AJ, Garssen MPJ, Gijsbers CJ, de Rijk MC, Visser LH, Blom RJ, Linssen WHJP, van der Kooi EL, Verschuuren JJGM, van Koningsveld R, Dieks RJG, Gilhuis HJ, Jellema K, van der Ree TC, Bienfait HME, Faber CG, Lovenich H, van Engelen BGM, Groen RJ, Merkies ISJ, van Oosten BW, van der Pol WL, van der Meulen WDM, Badrising UA, Stevens M, Breukelman AJ, Zwetsloot CP, van der Graaff MM, Wohlgemuth M, Hughes RAC, Cornblath DR, van Doorn PA; Dutch GBS Study Group. Walgaard C, et al. Among authors: badrising ua. Lancet Neurol. 2021 Apr;20(4):275-283. doi: 10.1016/S1474-4422(20)30494-4. Epub 2021 Mar 17. Lancet Neurol. 2021. PMID: 33743237 Clinical Trial.
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Among authors: badrising ua. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.
A protocol to develop clinical guidelines for inclusion-body myositis.
Jones KL, Sejersen T, Amato AA, Hilton-Jones D, Schmidt J, Wallace AC, Badrising UA, Rose MR; IBM Guideline Development Group. Jones KL, et al. Among authors: badrising ua. Muscle Nerve. 2016 Apr;53(4):503-7. doi: 10.1002/mus.25036. Epub 2016 Feb 22. Muscle Nerve. 2016. PMID: 26800092 Free PMC article. Review.
Facioscapulohumeral muscular dystrophy-Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease.
Vincenten SCC, Van Der Stoep N, Paulussen ADC, Mul K, Badrising UA, Kriek M, Van Der Heijden OWH, Van Engelen BGM, Voermans NC, De Die-Smulders CEM, Lassche S. Vincenten SCC, et al. Among authors: badrising ua. Clin Genet. 2022 Feb;101(2):149-160. doi: 10.1111/cge.14031. Epub 2021 Aug 1. Clin Genet. 2022. PMID: 34297364 Free PMC article. Review.
Teaching NeuroImages: A protruding asymmetrical belly.
Straathof CSM, Badrising UA. Straathof CSM, et al. Among authors: badrising ua. Neurology. 2017 Dec 12;89(24):e288-e289. doi: 10.1212/WNL.0000000000004738. Neurology. 2017. PMID: 29229693 No abstract available.
Interventions for dysphagia in long-term, progressive muscle disease.
Jones K, Pitceathly RD, Rose MR, McGowan S, Hill M, Badrising UA, Hughes T. Jones K, et al. Among authors: badrising ua. Cochrane Database Syst Rev. 2016 Feb 9;2(2):CD004303. doi: 10.1002/14651858.CD004303.pub4. Cochrane Database Syst Rev. 2016. PMID: 26859621 Free PMC article. Review.
1st FSHD European Trial Network workshop:Working towards trial readiness across Europe.
Voermans NC, Vriens-Munoz Bravo M, Padberg GW, Laforêt P; FSHD European Trial Network workshop study group; van Alfen N, Attarian S, Badrising UA, Bugiardini P, Camano González P, Carlier RY, Desguerre I, Diaz-Manera J, Dumonceaux J, van Engelen BG, Evangelista T, Khosla S, Lópezde Munain A, van der Maarel SM, Mejat A, Monforte M, Montagnese F, Mul K, Oflazer P, Porter B, Quijano Roy S, Ricci E, Sacconi S, Sansone VA, Schoser B, Statland J, Stumpe E, Tasca G, Tawil R, Turner C, Vissing J. Voermans NC, et al. Among authors: badrising ua. Neuromuscul Disord. 2021 Sep;31(9):907-918. doi: 10.1016/j.nmd.2021.07.013. Epub 2021 Jul 24. Neuromuscul Disord. 2021. PMID: 34404575 No abstract available.
Detecting dysphagia in inclusion body myositis.
Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Cox FM, et al. Among authors: badrising ua. J Neurol. 2009 Dec;256(12):2009-13. doi: 10.1007/s00415-009-5229-9. Epub 2009 Jul 15. J Neurol. 2009. PMID: 19603245 Free PMC article.
Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement.
Mellion ML, Ronco L, Berends CL, Pagan L, Brooks S, van Esdonk MJ, van Brummelen EMJ, Odueyungbo A, Thompson LA, Hage M, Badrising UA, Raines S, Tracewell WG, van Engelen B, Cadavid D, Groeneveld GJ. Mellion ML, et al. Among authors: badrising ua. Br J Clin Pharmacol. 2021 Dec;87(12):4658-4669. doi: 10.1111/bcp.14884. Epub 2021 May 14. Br J Clin Pharmacol. 2021. PMID: 33931884 Free article. Clinical Trial.
34 results